Completed PHASE2 INTERVENTIONAL 2-arm NCT01513135

A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers (ISS T-003)

A Phase Il, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers

Sponsor: Barbara Ensoli, MD

Conditions HIV Infections

Interventions Placebo Tat

Updated 5 times since 2017 Last updated: Mar 3, 2016 Started: Mar 31, 2012 Primary completion: May 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on HIV Infections, this trial is completed. The trial is conducted by Barbara Ensoli, MD and has accumulated 5 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Barbara Ensoli, MD
Italian Ministry of Foreign Affairs - General Direction for Cooperation and Development

Data source: Istituto Superiore di Sanità

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Medunsa, South Africa